# Michelle Snyder

> Michelle Snyder is a Series B investor at McKesson Ventures backing Health Care. See 2 investments, check sizes, portfolio and contact details. Updated Oct…

- Type: Angel Investor
- Fund: [McKesson Ventures](https://shizune.co/investors/profile/mckesson-ventures)
- Location: San Francisco, United States
- Total investments: 2
- Last investment: Mar 2025
- Lead investor: 50%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/michellensnyder
- X (Twitter): http://twitter.com/mnsnyder

Michelle Snyder is a Series B investor at McKesson Ventures in San Francisco focused on Health Care and Information Technology. Michelle Snyder - Partner @ McKesson Ventures

## Contacts

5 contacts available for Michelle Snyder: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/michelle-snyder?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 100% |
| Information Technology | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lumata Health | Lumata Health is a technology-driven healthcare startup focused on preventing blindness from chronic eye conditions, managing thousands of people at risk of vision loss across the United States. Founded in 2017 by an ophthalmologist and retina specialist in practice for over 30 years, Stephen R. Fransen, MD, and supported by more than 30 industryluminaries and influencers on its Advisory Board, Lumata Health aims to stop preventable blindness with a human-led, intelligent care coordination and management platform that’s almost always free to the patient. The company partners with physicians, payers and health systems to offer turnkey care management services provided by eye care experts who are supported by cutting edge technology and data science. Lumata Health’s programs improve clinical outcomes, patient satisfaction, and clinic staff efficiency by providing between-visit patient assistance and care coordination for patients with chronic eye diseases such as diabetic retinopathy, macular degeneration, glaucoma, and dry eye. | $23M | Series B | Mar 05, 2025 | https://lumatahealth.com/ |
| Atropos Health | Atropos Health rapidly provides personalized real-world evidence for any clinical decision | $33M | Series B | May 23, 2024 | http://www.atroposhealth.com |

2 of 2 investments shown.

## Co-investors
- [Cencora Ventures](https://shizune.co/investors/profile/cencora-ventures) — VC Fund, 2 deals together
- [Breyer Capital](https://shizune.co/investors/profile/breyer-capital) — VC Fund, 1 deal together
- [Cortado Ventures](https://shizune.co/investors/profile/cortado-ventures) — VC Fund, 1 deal together
- [Emerson Collective](https://shizune.co/investors/profile/emerson-collective) — VC Fund, 1 deal together
- [LRVHealth](https://shizune.co/investors/profile/long-river-ventures) — VC Fund, 1 deal together
- [Merck Global Health Innovation Fund](https://shizune.co/investors/profile/merck-global-health-innovation-fund) — VC Fund, 1 deal together

## About McKesson Ventures

VC Fund · San Francisco, United States

McKesson Ventures they help entrepreneurs in healthcare technology and services to create efficient health care delivery systems for key stakeholders on all sides of the health care economy.

5 contacts available at McKesson Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Carrie Williams | Vice President and Partner | https://shizune.co/investors/profile/carrie-williams |
| Dave Schulte | SVP, Managing Director | https://shizune.co/investors/profile/dave-schulte |
| Ed Albrektsen | Director, Vendor Solutions & Audit | https://shizune.co/investors/profile/ed-albrektsen |
| Jennifer Carter | Vice President, Portfolio Development; Partner & Vice President Venture Operations | https://shizune.co/investors/profile/jennifer-carter-2 |
| Michelle Snyder | Partner | https://shizune.co/investors/profile/michelle-snyder |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Michelle Snyder invest in?

Michelle Snyder invests primarily in Health Care and Information Technology startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Michelle Snyder?

Public channels for Michelle Snyder include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Michelle Snyder last invest?

The most recent investment recorded for Michelle Snyder closed in Mar 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co